- Home
- CCM vs OSRH Comparison
CCM vs OSRH Comparison
Compare CCM & OSRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CCM | OSRH |
|---|---|---|
| Founded | 1997 | N/A |
| Country | China | United States |
| Employees | N/A | 22 |
| Industry | Medical/Nursing Services | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.4M | 17.9M |
| IPO Year | 2009 | N/A |
Fundamental Metrics
Financial Performance| Metric | CCM | OSRH |
|---|---|---|
| Price | $4.73 | $0.41 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 38.1K | ★ 1.1M |
| Earning Date | 05-12-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $9.30 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.18 | $0.38 |
| 52 Week High | $10.77 | $1.79 |
Technical Indicators
Market Signals| Indicator | CCM | OSRH |
|---|---|---|
| Relative Strength Index (RSI) | 46.41 | 39.47 |
| Support Level | $4.46 | $0.40 |
| Resistance Level | $5.41 | $0.47 |
| Average True Range (ATR) | 0.44 | 0.04 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 16.51 | 20.80 |
Price Performance
Historical ComparisonAbout CCM Concord Medical Services Holdings Limited
Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Geographically, the company derives revenue from PRC.
About OSRH OSR Holdings Inc.
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea. The company's pipeline products include: Vaximm, Darnatein, Woori IO, and RMC.